{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:28:44Z","timestamp":1793035724299,"version":"4.5.0"},"reference-count":100,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic renal disease, with an estimated prevalence between 1:1000 and 1:2500. It is mostly caused by mutations of the PKD1 and PKD2 genes encoding polycystin 1 (PC1) and polycystin 2 (PC2) that regulate cellular processes such as fluid transport, differentiation, proliferation, apoptosis and cell adhesion. Reduction of calcium ions and induction of cyclic adenosine monophosphate (sAMP) promote cyst enlargement by transepithelial fluid secretion and cell proliferation. Abnormal activation of MAPK\/ERK pathway, dysregulated signaling of heterotrimeric G proteins, mTOR, phosphoinositide 3-kinase, AMPK, JAK\/STAT activator of transcription and nuclear factor kB (NF-kB) are involved in cystogenesis. Another feature of cystic tissue is increased extracellular production and recruitment of inflammatory cells and abnormal connections among cells. Moreover, metabolic alterations in cystic cells including defective glucose metabolism, impaired beta-oxidation and abnormal mitochondrial activity were shown to be associated with cyst expansion. Although tolvaptan has been recently approved as a drug that slows ADPKD progression, some patients do not tolerate tolvaptan because of frequent aquaretic. The advances in the knowledge of multiple molecular pathways involved in cystogenesis led to the development of animal and cellular studies, followed by the development of several ongoing randomized controlled trials with promising drugs. Our review is aimed at pathophysiological mechanisms in cystogenesis in connection with the most promising drugs in animal and clinical studies.<\/jats:p>","DOI":"10.3390\/ijms23063317","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T21:30:14Z","timestamp":1647811814000},"page":"3317","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment"],"prefix":"10.3390","volume":"23","author":[{"given":"Jana","family":"Reiterov\u00e1","sequence":"first","affiliation":[{"name":"Department of Nephrology, First Faculty of Medicine, Charles University, General University Hospital in Prague, 128 08 Prague, Czech Republic"},{"name":"Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, General University Hospital in Prague, 128 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6982-0689","authenticated-orcid":false,"given":"Vladim\u00edr","family":"Tesa\u0159","sequence":"additional","affiliation":[{"name":"Department of Nephrology, First Faculty of Medicine, Charles University, General University Hospital in Prague, 128 08 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,19]]},"reference":[{"key":"ref_1","first-page":"1356","article-title":"Prevalence of autosomal dominant polycystic kidney disease in the European Union","volume":"32","author":"Willey","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1681\/ASN.2018050493","article-title":"Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing","volume":"29","author":"Lanktree","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/ndt\/gfs551","article-title":"Epidemiology of autosomal-dominant polycystic kidney disease: An in-depth clinical study for south-western Germany","volume":"28","author":"Neumann","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","article-title":"Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: Prevalence and survival\u2014An analysis of data from the ERA-EDTA Registry","volume":"29","author":"Spithoven","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort1","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"eaat9819","DOI":"10.1126\/science.aat9819","article-title":"Structure of the human PKD1-PKD2 complex","volume":"80","author":"Su","year":"2018","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.bbadis.2011.01.011","article-title":"Fluid transport and cystogenesis in autosomal dominant polycystic kidney disease","volume":"1812","author":"Terryn","year":"2011","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/joim.12654","article-title":"The vasopressin system: New insights for patients with kidney diseases: Epidemiological evidence and therapeutic perspectives","volume":"282","author":"Clark","year":"2017","journal-title":"J. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1590\/S0100-879X2011007500068","article-title":"Molecular and cellular pathogenesis of autosomal dominant polycystic kidney disease","volume":"44","author":"Bastos","year":"2011","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","article-title":"cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells","volume":"11","author":"Hanaoka","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1755-8417-2-6","article-title":"Emerging evidence of a link between the polycystins and the mTOR pathways","volume":"2","author":"Boletta","year":"2009","journal-title":"Pathogenetics"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Dere, R., Wilson, P.D., Sandford, R.N., and Walker, C.L. (2010). Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009239"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"36431","DOI":"10.1074\/jbc.M109.068916","article-title":"Polycystin-1 interacts with inositol 1,4,5-trisphosphate receptor to modulate intracellular Ca2+ signaling with implications for polycystic kidney disease","volume":"284","author":"Li","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1159\/000330080","article-title":"Polycystin-1,2, and STIM1 interact with IP 3 R to Modulate ER Ca2+ release through the PI3K\/Akt pathway","volume":"27","author":"Santoso","year":"2011","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"a011189","DOI":"10.1101\/cshperspect.a011189","article-title":"PI3K-PKB\/Akt Pathway","volume":"4","author":"Hemmings","year":"2012","journal-title":"Cold Spring Harb. Perspect Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1681\/ASN.2005050534","article-title":"Polycystin-1 Induces Resistance to Apoptosis through the Phosphatidylinositol 3-Kinase\/Akt Signaling Pathway","volume":"17","author":"Boca","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0092-8674(02)00716-X","article-title":"PKD1 Induces p21waf1 and Regulation of the Cell Cycle via Direct Activation of the JAK-STAT Signaling Pathway in a Process Requiring PKD2","volume":"109","author":"Bhunia","year":"2002","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.devcel.2005.12.005","article-title":"Polycystin-1, STAT6, and P100 Function in a Pathway that Transduces Ciliary Mechanosensation and is Activated in Polycystic Kidney Disease","volume":"10","author":"Low","year":"2006","journal-title":"Dev. Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e23650","DOI":"10.4161\/jkst.23650","article-title":"Regulation of STATs by polycystin-1 and their role in polycystic kidney disease","volume":"2","author":"Weimbs","year":"2013","journal-title":"JAK STAT"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/ncb1326","article-title":"Polycystin-1 and polycystin-2 regulate the cell cycle through the helix-loop-helix inhibitor Id2","volume":"7","author":"Li","year":"2005","journal-title":"Nat. Cell Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1074\/jbc.273.11.6013","article-title":"The Polycystic Kidney Disease 1 Gene Product Mediates Protein Kinase C \u03b1-dependent and c-Jun N-terminal Kinase-dependent Activation of the Transcription Factor AP-1","volume":"273","author":"Arnould","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1128\/MCB.19.5.3423","article-title":"Cellular Activation Triggered by the Autosomal Dominant Polycystic Kidney Disease Gene Product PKD2","volume":"19","author":"Arnould","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1083\/jcb.200111073","article-title":"NFAT: Ubiquitous regulator of cell differentiation and adaptation","volume":"156","author":"Horsley","year":"2002","journal-title":"J. Cell Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"55455","DOI":"10.1074\/jbc.M402905200","article-title":"Polycystin-1 Activates the Calcineurin\/NFAT (Nuclear Factor of Activated T-cells) Signaling Pathway","volume":"279","author":"Puri","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1038\/sj.onc.1204386","article-title":"Partners in transcription: NFAT and AP-1","volume":"20","author":"Rao","year":"2001","journal-title":"Oncogene"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"dev146589","DOI":"10.1242\/dev.146589","article-title":"Wnt signaling in development and tissue homeostasis","volume":"145","author":"Steinhart","year":"2018","journal-title":"Development"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","article-title":"Wnt\/\u03b2-Catenin Signaling in Development and Disease","volume":"127","author":"Clevers","year":"2006","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/bdrc.20195","article-title":"Noncanonical Wnt signaling in vertebrate development, stem cells, and diseases","volume":"90","author":"Sugimura","year":"2010","journal-title":"Birth Defects Res. Part C Embryo Today Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.molmed.2010.05.004","article-title":"Cystic kidney disease: The role of Wnt signaling","volume":"16","author":"Lancaster","year":"2010","journal-title":"Trends Mol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease","volume":"371","author":"Torres","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologuous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin dierectly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease","volume":"367","author":"Torres","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicentric, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: The TEMPO 4:4 trial","volume":"33","author":"Torres","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease","volume":"377","author":"Torres","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.ekir.2021.05.037","article-title":"Tolvaptan in ADPKD Patients with Very Low Kidney Function","volume":"6","author":"Torres","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_41","first-page":"942","article-title":"The PROPKD score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"6","author":"Audrezet","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ekir.2016.08.001","article-title":"Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial","volume":"1","author":"Irazabal","year":"2016","journal-title":"Kidney Int. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): A randomized placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.ajkd.2013.10.011","article-title":"Rationale and design of the DIPAK 1 study: A randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease","volume":"63","author":"Meijer","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces volume of polycystic liver: A randomized, double-blind, placebo-controlled trial","volume":"137","author":"Nevens","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The long-term outcome of patients with polycystic liver disease treated with lanreotide","volume":"35","author":"Chrispijn","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1159\/000500667","article-title":"Effect of a vasopressin V2 receptor antagonist on polycystic kidney disease development in a rat model","volume":"49","author":"Wang","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11095-019-2726-0","article-title":"Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney Disease Using Quantitative Systems Toxicology Modeling","volume":"37","author":"Woodhead","year":"2020","journal-title":"Pharm. Res."},{"key":"ref_51","first-page":"529","article-title":"Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis","volume":"19","author":"Xu","year":"2006","journal-title":"J. Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1074\/jbc.RA118.001846","article-title":"A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector","volume":"293","author":"Yanda","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Yuajit, C., Homvisasevongsa, S., Chatsudthipong, L., Soodvilai, S., Muanprasat, C., and Chatsudthipong, V. (2013). Steviol Reduces MDCK Cyst Formation and Growth by Inhibiting CFTR Channel Activity and Promoting Proteasome-Mediated CFTR Degradation. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058871"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bcp.2018.05.005","article-title":"Lansoprazole reduces renal cyst in polycystic kidney disease via inhibition of cell proliferation and fluid secretion","volume":"154","author":"Nantavishit","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ki.2008.246","article-title":"KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal dominant polycystic kidney disease","volume":"74","author":"Albaqumi","year":"2008","journal-title":"Kidney Int."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1038\/s41467-020-18104-5","article-title":"Cyst growth in ADPKD is prevented by pharmacological and genetic inhibition of TMEM16A in vivo","volume":"11","author":"Cabrita","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Miner, K., Labitzke, K., Liu, B., Wang, P., Henckels, K., Gaida, K., Elliott, R., Chen, J.J., Liu, L., and Leith, A. (2019). Drug repurposing: The anthelmintics niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways. Front. Pharmacol., 14.","DOI":"10.1101\/254888"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejmech.2018.10.002","article-title":"Synthesis and biological evaluation of novel Ani9 derivatives as potent and selective ANO1 inhibitors","volume":"160","author":"Seo","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"C522","DOI":"10.1152\/ajpcell.00163.2010","article-title":"c-Src inactivation reduces renal peithelial cell-matrix adhesion, proliferation, and cyst formation","volume":"302","author":"Elliot","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1681\/ASN.2016111232","article-title":"Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease","volume":"28","author":"Tesar","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5527\/wjn.v6.i4.188","article-title":"Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease","volume":"6","author":"Sweeney","year":"2017","journal-title":"World J. Nephrol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/labinvest.2008.104","article-title":"PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta","volume":"89","author":"Kawai","year":"2009","journal-title":"Lab. Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1152\/ajprenal.00090.2009","article-title":"PPARgamma agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line","volume":"297","author":"Nofziger","year":"2009","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41598-020-58382-z","article-title":"Renal cyst growth is attenuated by a combination of tolvaptan and pioglitazon, while pioglitazone treatment alone is not effective","volume":"10","author":"Kanhai","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ebiom.2016.01.027","article-title":"Fatty Acid Oxidation is Impaired in An Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease","volume":"5","author":"Menezes","year":"2016","journal-title":"eBioMedicine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1038\/s41598-017-07300-x","article-title":"Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency","volume":"7","author":"Chang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2021.06.013","article-title":"Primary results of the randomized trial of metformin administration in polycystic kideny disease (TAME PKD)","volume":"100","author":"Perrone","year":"2021","journal-title":"Kidney Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3109\/00365590903359908","article-title":"Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease","volume":"44","author":"Fassett","year":"2009","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_71","first-page":"109","article-title":"Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease, a secondary analysis of the HALT PKD Trials","volume":"13","author":"Brosnahan","year":"2017","journal-title":"Curr. Hypertens. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","article-title":"cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracelllular signal-regulated kinase pathway","volume":"57","author":"Yamaguchi","year":"2000","journal-title":"Kidney Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1093\/ndt\/gfr432","article-title":"The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis","volume":"26","author":"Buchholz","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"109495","DOI":"10.1016\/j.cellsig.2019.109495","article-title":"Metabolic reprogramming and the role of mitochondria in polycystic kidney disease","volume":"67","author":"Podrini","year":"2019","journal-title":"Cell. Signal."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"F726","DOI":"10.1152\/ajprenal.00551.2015","article-title":"A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease","volume":"310","author":"Kipp","year":"2016","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2015020132","article-title":"Food Restriction Ameliorates the Development of Polycystic Kidney Disease","volume":"27","author":"Warner","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.kint.2016.10.018","article-title":"Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease","volume":"91","author":"Torres","year":"2017","journal-title":"Kidney Int."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Riwanto, M., Kapoor, S., Rodriguez, D., Edenhofer, I., Segerer, S., and W\u00fcthrich, R.P. (2016). Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycystic Kidney Disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0146654"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease","volume":"363","author":"Walz","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease","volume":"363","author":"Serra","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_84","first-page":"2492","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"329","author":"Akizawa","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"eaba3613","DOI":"10.1126\/scitranslmed.aba3613","article-title":"Activation of NRF2 ameliorates oxidative stress and cystogenesis in autosomal dominant polycystic kidney disease","volume":"12","author":"Lu","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1681\/ASN.2008090927","article-title":"Calcimimetic Inhibits Late-Stage Cyst Growth in ADPKD","volume":"20","author":"Gattone","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_87","first-page":"e21874","article-title":"Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease","volume":"35","author":"Wang","year":"2021","journal-title":"FASEB J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e172811","DOI":"10.1016\/j.ejphar.2019.172811","article-title":"Triptolide inhibits PDGF-induced proliferation of ASMCs therough G0\/G1 cell cycle arrest and suppression of the AKT\/NK-\u03baB\/cyclinD1 signaling pathway","volume":"867","author":"He","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.ajkd.2014.01.418","article-title":"Triptolide-Containing Formulation in Patients With Autosomal Dominant Polycystic Kidney Disease and Proteinuria: An Uncontrolled Trial","volume":"63","author":"Chen","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.4161\/cc.22375","article-title":"CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD","volume":"11","author":"Bukanov","year":"2012","journal-title":"Cell Cycle"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.kint.2016.01.026","article-title":"Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease","volume":"90","author":"Cebotaru","year":"2016","journal-title":"Kidney Int."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"21819","DOI":"10.1073\/pnas.0911987106","article-title":"Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models","volume":"106","author":"Cao","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"109526","DOI":"10.1016\/j.cellsig.2020.109526","article-title":"Glycosphingolipid metabolism and polycystic kidney disease","volume":"69","author":"Natoli","year":"2020","journal-title":"Cell. Signal."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nm.2171","article-title":"Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models","volume":"16","author":"Natoli","year":"2010","journal-title":"Nat. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000369149","article-title":"Effects of MCP-1 Inhibition by Bindarit Therapy in a Rat Model of Polycystic Kidney Disease","volume":"129","author":"Zoja","year":"2014","journal-title":"Nephron"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nm1783","article-title":"A tumor necrosis factor-\u03b1\u2013mediated pathway promoting autosomal dominant polycystic kidney disease","volume":"14","author":"Li","year":"2008","journal-title":"Nat. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2020071094","article-title":"TWEAK signaling pathway blockade slows cyst growth and disease progression in autosomal dominant polycystic kidney disease","volume":"32","author":"Cordido","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"10765","DOI":"10.1073\/pnas.1301693110","article-title":"miR-17 92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease","volume":"110","author":"Patel","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1038\/s41467-019-11918-y","article-title":"Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 fot the treatment of polycystic kidney disease","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1096\/fj.201800563RR","article-title":"Impact of miR-192 and miR-194 on cyst enlargement through EMT in autosomal dominant polycystic kidney disease","volume":"33","author":"Kim","year":"2018","journal-title":"FASEB J."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/6\/3317\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:39:27Z","timestamp":1760135967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/6\/3317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,19]]},"references-count":100,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["ijms23063317"],"URL":"https:\/\/doi.org\/10.3390\/ijms23063317","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,19]]}}}